相关实验视频

Updated: Jun 28, 2025

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

对T2DM小鼠多个标的特定聚合度的基托醇糖的作用

Jiangshan You¹, Mengyao Zhao^1,2, Shumin Chen¹

¹State Key Laboratory of Bioreactor Engineering, School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.

Bioresources and bioprocessing

|April 22, 2024

概括

基醇糖 (COS) 显示出对治疗2型糖尿病的巨大潜力. 这种天然化合物有效降低血糖和脂质,改善胰岛素敏感性,并保护胰腺小岛细胞,提供了一个有前途的治疗途径.

科学领域:

海洋生物技术海洋生物技术
生物化学生化学
内分泌学在内分泌学.

背景情况:

来自海洋来源的基醇糖 (COS) 具有多种生理活动.
在代谢障碍方面,COS的低血糖效应具有显著的研究兴趣.

研究的目的:

在2型糖尿病 (T2DM) 的小鼠模型中评估COS的治疗疗效.

主要方法:

给T2DM小鼠使用COS.
对血糖和脂质水平的评估.
对葡萄糖耐受性的评估.
在体外α-葡萄糖酶抑制试验.
分子对接研究. 分子对接研究.
分析胰岛素信号传递和糖原合成.
对葡萄糖生成的研究.
评估小岛细胞功能和胰岛素分泌.

主要成果:

COS显著降低了血糖和脂质水平,并改善了葡萄糖耐受性.
COS表现出强大的α-葡萄糖酶抑制活性,降低了餐后葡萄糖.
分子对接表明COS与α-glucosidase的相互作用.
COS增强了胰岛素信号传递,糖原合成和受保护的小岛细胞,降低了胰岛素抵抗力.
COS增加了胰岛素的分泌.

结论:

COS显示出显著的,多目标的低血糖效应.
作为T2DM和代谢综合征的新型预防或治疗剂,COS显示出前景.

关键词:

基托醇醇糖化物基托醇糖化物糖尿病是一种糖尿病.低血糖的影响低血糖效应胰岛素耐药性胰岛素耐药性是一种

更多相关视频

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...